Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

British Journal of Cancer
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. british journal of cancer
  3. regular article
  4. article
The topology of plasminogen binding and activation on the surface of human breast cancer cells
Download PDF
Download PDF
  • Regular Article
  • Open access
  • Published: 11 September 2001

The topology of plasminogen binding and activation on the surface of human breast cancer cells

  • N M Andronicos1 &
  • M Ranson1 

British Journal of Cancer volume 85, pages 909–916 (2001)Cite this article

  • 1096 Accesses

  • 33 Citations

  • 6 Altmetric

  • Metrics details

This article has been updated

Abstract

The urokinase-dependent activation of plasminogen by breast cancer cells plays an important role in metastasis. We have previously shown that the metastatic breast cancer cell line MDA-MB-231 over-expresses urokinase and binds and efficiently activates plasminogen at the cell surface compared to non-metastatic cells. The aim of this study was to further characterise plasminogen binding and determine the topology of cell surface-bound plasminogen in terms of its potential for activation. The lysine-dependent binding of plasminogen at 4°C to MDA-MB-231 cells was stable and resulted in an activation-susceptible conformation of plasminogen. Topologically, a fraction of bound plasminogen was co-localised with urokinase on the surfaces of MDA-MB-231 cells where it could be activated to plasmin. At 37°C plasmin was rapidly lost from the cell surface. Apart from actin, other candidate plasminogen receptors were either not expressed or did not co-localise with plasminogen at the cell surface. Thus, based on co-localisation with urokinase, plasminogen binding is partitioned into two functional pools on the surface of MDA-MB-231 cells. In conclusion, these results shed further light on the functional organisation of the plasminogen activation cascade on the surface of a metastatic cancer cell. © 2001 Cancer Research Campaign http://www.bjcancer.com

Similar content being viewed by others

Uracil derivatives/ursolic acid hybrids - naturally derived compounds as anticancer agents

Article Open access 06 August 2025

Non-thermal plasma as promising anti-cancer therapy against bladder cancer by inducing DNA damage and cell cycle arrest

Article Open access 17 January 2025

Octa- square split ring-shaped supercell-based plasmonic metamaterials for enhanced dual-spectral detection of cancer biomarkers

Article Open access 26 September 2025

Article PDF

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  • Andronicos NM, Ranson M, Bognacki J and Baker MS (1997) The human ENO1 gene product (recombinant human α-enolase) displays characteristics required for a plasminogen binding protein. Biochim Biophys Acta 1337: 27–39

    Article  CAS  Google Scholar 

  • Andronicos NM, Baker MS, Lackmann M and Ranson M (2000) Deconvolution of the binding of plasminogen to its receptor α-enolase. Fibrinol Proteol 14: 327–336

    Article  CAS  Google Scholar 

  • Bastiaens PIH and Jovin TM (1996) Microspectroscopic tracks the intracellular processing of a signal transduction protein: Fluorescently-labeled protein kinase C β1. Proc Natl Acad Sci USA 93: 8407–8412

    Article  CAS  Google Scholar 

  • Christensen U and Molgaard L (1991) Stopped-flow kinetic studies of glu-plasminogen. Conformational changes triggered by AH-site ligand binding. FEBS Lett 278: 204–206

    Article  CAS  Google Scholar 

  • Cubellis MV, Nolli ML, Cassani G and Blasi F (1986) Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem 261: 15818–15822

    Google Scholar 

  • Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J and Lund LR (1999) Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 107: 120–127

    Article  CAS  Google Scholar 

  • Dudani AK and Ganz PR (1996) Endothelial cell surface actin serves as a plasminogen binding site for plasminogen, tissue plasminogen activator and lipoprotein (a). Br J Haematol 95: 168–178

    Article  CAS  Google Scholar 

  • Duffy MJ, Maguire TM, McDermott EW and O’ Higgins N (1999) Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71: 130–135

    Article  CAS  Google Scholar 

  • Ellis V, Whawell SA, Werner F and Deadman JJ (1999) Assembly of urokinase-receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen. Biochemistry 38: 651–659

    Article  CAS  Google Scholar 

  • Felez J (1998) Plasminogen binding to cell surfaces. Fibrinol Proteol 12: 183–189

    Article  CAS  Google Scholar 

  • Lind SE and Smith CJ (1993) Actin stimulates plasmin generation by tissue and urokinase-type plasminogen activators. Arch Biochem Biophys 307: 138–145

    Article  CAS  Google Scholar 

  • Markus G (1996) Conformational changes in plasminogen, their effect on activation and agents that modulate activation rates – a review. Fibrinolysis 10: 75–85

    Article  CAS  Google Scholar 

  • O’Mullane MJ and Baker MS (1998) Loss of cell viability dramatically elevates cell-surface plasminogen binding and activation. Expt Cell Res 242: 153–164

    Article  Google Scholar 

  • Ranson M, Andronicos NM, O’ Mullane MJ and Baker MS (1998) Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins. Br J Cancer 77: 1586–1597

    Article  CAS  Google Scholar 

  • Redlitz A, Tan AK, Eaton DL and Plow EF (1995a) Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 96: 2534–2538

    Article  CAS  Google Scholar 

  • Redlitz A, Fowler BJ, Plow EF and Miles LA (1995b) The role of an enolase-related molecule in plasminogen binding to cells. Eur J Biochem 227: 407–415

    Article  CAS  Google Scholar 

  • Schmitt M, Wilhelm OG, Reuning U, Kruger A, Harbeck N, Lengyel E, Graeff H, Gansbacher B, Kessler H, Burgle M, Sturzebecher J, Sperl S and Magdolen V (2000) The urokinase plasminogen activation system as a novel target for tumour therapy. Fibrinol & Proteol 14: 114–132

    Article  CAS  Google Scholar 

  • Stonelake PS, Jones CE, Neoptolemos JP and Baker PR (1997) Proteinase inhibitors reduce basement membrane degradation by human breast cancer cells. Br J Cancer 75: 951–959

    Article  CAS  Google Scholar 

  • Vassalli J-D, Baccino D and Berlin D (1985) A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86–92

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biological Sciences, University of Wollongong, NSW 2522, Australia

    N M Andronicos & M Ranson

Authors
  1. N M Andronicos
    View author publications

    Search author on:PubMed Google Scholar

  2. M Ranson
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and permissions

About this article

Cite this article

Andronicos, N., Ranson, M. The topology of plasminogen binding and activation on the surface of human breast cancer cells. Br J Cancer 85, 909–916 (2001). https://doi.org/10.1054/bjoc.2001.2022

Download citation

  • Received: 20 October 2000

  • Revised: 05 July 2001

  • Accepted: 06 July 2001

  • Published: 11 September 2001

  • Issue date: 14 September 2001

  • DOI: https://doi.org/10.1054/bjoc.2001.2022

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • plasminogen binding
  • co-localisation
  • urokinase
  • breast cancer cells

This article is cited by

  • MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression

    • Marilyne Kpetemey
    • Subhamoy Dasgupta
    • Jamboor K. Vishwanatha

    Molecular Cancer (2015)

  • Improved Pharmacokinetic and Biodistribution Properties of the Selective Urokinase Inhibitor PAI-2 (SerpinB2) by Site-Specific PEGylation: Implications for Drug Delivery

    • Kara Lea Vine
    • Sergei Lobov
    • Marie Ranson

    Pharmaceutical Research (2015)

  • Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity

    • Gillian E Stillfried
    • Darren N Saunders
    • Marie Ranson

    Breast Cancer Research (2007)

  • Plasminogen and angiostatin interact with heat shock proteins

    • Anil K. Dudani
    • Jelica Mehic
    • Anthony Martyres

    Molecular and Cellular Biochemistry (2007)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Follow us on Twitter
  • Sign up for alerts
  • RSS feed

About the journal

  • Journal Information
  • Open access publishing
  • About the Editors
  • Contact
  • Special Issues
  • For Advertisers
  • Subscribe

Publish with us

  • For Authors & Referees
  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

British Journal of Cancer (Br J Cancer)

ISSN 1532-1827 (online)

ISSN 0007-0920 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited